Contact Us
Advancing medicine through the power of AI
Digital health is a rapidly expanding business area for the NEC Group. Within the Biomedical AI group at NEC Laboratories Europe, we address medical challenges across the full health and wellbeing spectrum – from disease prevention and diagnosis to treatment.
Cancer research for new immunotherapies
We develop advanced computational pipelines that combine bioinformatics and machine learning that are used by the wider NEC Bio group to design both personalized and shared cancer vaccines. These pipelines have been validated through wet-lab experiments and are currently undergoing clinical trials.
Combatting infectious disease
NEC is committed to combatting infectious disease and virus pandemics by using AI to gain a deeper understanding of disease and virus mechanisms and epidemiology. NEC collaborates with global partners such as the Coalition for Epidemic Preparedness Innovations (CEPI) to advance applied research in this area.
NEC Laboratories Europe is a leading contributor to NEC’s fight against infectious disease, which includes supporting the development of a prophylactic vaccine designed to offer broad protection against betacoronaviruses (the genus that includes SARS-CoV-2), in collaboration with
NEC OncoImmunity AS. Currently, we are working on predicting how viruses may evolve over time, with the goal of designing virus vaccines that are robust to future variants.
Chronic diseases management and prevention
We apply AI-driven approaches to chronic disease prevention and management by leveraging multi-modal biomedical data – including high-throughput omics, in particular proteomics, patient demographics, clinical notes, time-series data from vital signs, microbiome profiles, as well as lifestyle and symptom data collected via user apps.
By combining state-of-the-art AI, deep biological insights and real-world patient data, we are shifting healthcare from reactive treatment to proactive prevention – alleviating the long-term burden on both individuals and health systems.
NEC drug development network: advancing clinical therapies
Guided by NEC Bio B.V, which lead NEC drug development strategy, we work closely with NEC drug divisions and international partners to progress groundbreaking therapies for patients using advanced AI technologies.
Being part of the NEC Bio network connects organizations and researchers to a globally integrated ecosystem that unifies cutting‑edge AI technologies with advanced biomedical science, enabling faster, more precise drug discovery and development.
The network brings together specialized entities across Europe – such as NEC OncoImmunity in Norway, NEC Bio Therapeutics in Germany and ourselves – creating a streamlined structure that accelerates innovation from computational antigen prediction to clinical execution.
This cohesive framework strengthens global R&D capabilities and supports the development of personalized cancer vaccines and next‑generation infectious disease vaccines. It also leverages best‑in‑class AI and machine‑learning platforms, such as the NEC Immune Profiler, to increase the probability of clinical success and ultimately drive the delivery of novel therapies to patients worldwide.
